NCT02116959 is a Phase 1 clinical trial of Melphalan in Advanced Intra-Ocular Retinoblastoma, sponsored by University of California, San Francisco.

Who is sponsoring NCT02116959?

NCT02116959 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT02116959?

Interventions in NCT02116959: Melphalan, Carboplatin, Etoposide, Vincristine.

What condition does NCT02116959 study?

NCT02116959 studies Advanced Intra-Ocular Retinoblastoma, Retinoblastoma.

Is NCT02116959 still recruiting?

NCT02116959 is currently terminated. Last updated 16 April 2020.

Last reviewed 2020-04-16 · How we verify

NCT02116959

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma

Terminated Phase 1 Last updated 16 April 2020

What this trial tests

Phase 1 trial testing Melphalan in Advanced Intra-Ocular Retinoblastoma in 6 participants. Terminated before completion.

Timeline

23 July 2014

Primary endpoint
25 May 2019

25 May 2019

Quick facts

Lead sponsor	University of California, San Francisco
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	23 July 2014
Primary completion	25 May 2019
Estimated completion	25 May 2019
Sites	1 location across United States

Drugs / interventions tested

Melphalan (melphalan) — full drug profile →
Carboplatin (Carboplatin) — full drug profile →
Etoposide (etoposide) — full drug profile →
Vincristine (vincristine) — full drug profile →

Conditions studied

Advanced Intra-Ocular Retinoblastoma — all drugs for Advanced Intra-Ocular Retinoblastoma →
Retinoblastoma — all drugs for Retinoblastoma →

Sponsor

University of California, San Francisco

Who can join

Adults 3 Months to 18, any sex, with Advanced Intra-Ocular Retinoblastoma or Retinoblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test the safety of the treatment combination of alternating standard chemotherapy and another (melphalan) chemotherapy at different interval schedules. Researchers want to find out what effects, good and/or bad, the treatment combination has on the patients and their retinoblastoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Retinoblastoma: An update on genetic origin, classification, conventional to next-generation treatment strategies.
Pareek A, Kumar D, Pareek A, Gupta MM, et al · · 2024 · cited 10× · PMID 38975183 · DOI 10.1016/j.heliyon.2024.e32844

Verify or expand the search:

Other trials of Melphalan

Trials testing the same drug.

NCT06954987 — Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell · Phase 2 · not yet recruiting
NCT06996119 — Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versu · Phase 1 · not yet recruiting
NCT07228624 — Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplas · Phase 2 · recruiting
NCT06287944 — 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiati · Phase 1 · recruiting
NCT06815003 — Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di · Phase 2 · recruiting

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02116959 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 16 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02116959.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing